SNCA and Parkinson disease: This study successfully demonstrates the development of a novel IN delivery system utilizing albumin-coated liposomes (C-LipSel-siSNCA2) for the co-delivery of Sel and α-synuclein-targeting siRNA, providing a promising therapeutic approach for PD.